Cosmo Godino

List of Publications by Year
in descending order

145 papers	4,532 citations	87888 38 h-index	118850 62 g-index
148 all docs	148 docs citations	148 times ranked	4586 citing authors

#	Article	IF	Citations
1	Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (â‰¥85 years old) with non-valvular atrial fibrillation. Minerva Medica, 2023, 114, .	0.9	4
2	Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight. European Journal of Clinical Investigation, 2022, 52, e13658.	3.4	6
3	Abnormal Angle between Interatrial Septum and Mitral Valve Plane: an Unfavorable Predictor for MitraClip Procedure. Journal of Cardiovascular Imaging, 2022, 29, 138-139.	0.7	0
4	Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome. Canadian Journal of Cardiology, 2022, 38, 320-329.	1.7	20
5	Predictors of optimal procedural result after transcatheter edgeâ€toâ€edge mitral valve repair in secondary mitral regurgitation. Catheterization and Cardiovascular Interventions, 2022, 99, 1626-1635.	1.7	11
6	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
7	Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion. American Journal of Cardiology, 2022, 171, 105-114.	1.6	3
8	Meta-Analysis of Relation Between Left Ventricular Dysfunction and Outcomes After Transcatheter Mitral Edge-to-Edge Repair. American Journal of Cardiology, 2022, 175, 88-96.	1.6	1
9	Edgeâ€toâ€edge percutaneous mitral repair for functional ischaemic and nonâ€ischaemic mitral regurgitation: a systematic review and metaâ€analysis. ESC Heart Failure, 2022, 9, 3177-3187.	3.1	5
10	Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-. International Journal of Cardiology, 2021, 324, 261-266.	1.7	65
11	Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. American Journal of Cardiology, 2021, 143, 51-59.	1.6	8
12	Italian Society of Interventional Cardiology (<scp>GIse</scp>) registry Of Transcatheter treatment of mitral valve r<scp>egurgitaTiOn</scp> (<scp>GIOTTO</scp>): impact of valve disease aetiology and residual mitral regurgitation after <scp>MitraClip</scp> implantation. European Journal of Heart Failure, 2021, 23, 1364-1376.	7.1	49
13	Use of <scp>edgeâ€toâ€edge</scp> percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience (<scp>MITRAâ€SHOCK</scp> study). Catheterization and Cardiovascular Interventions, 2021, 98, E163-E170.	1.7	16
14	Strategies for bridge to heart transplantation: Percutaneous mitral valve repair and LVAD. Journal of Heart and Lung Transplantation, 2021, 40, 536-537.	0.6	2
15	Transcatheter therapies for secondary mitral regurgitation in advanced heart failure: what are we aiming for?. Heart Failure Reviews, 2021, , 1.	3.9	2
16	Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation. Panminerva Medica, 2021, , .	0.8	7
17	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. International Journal of Cardiology, 2021, 344, 240-245.	1.7	17
18	Cardiac and sudden death after chronic total occlusion percutaneous coronary intervention: Prognostic role of the target vessel. Catheterization and Cardiovascular Interventions, 2021, 97, E789-E800.	1.7	2

#	Article	IF	Citations
19	Mitral valve surgery after a failed MitraClip procedure. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 380-385.	1.1	14
20	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). Catheterization and Cardiovascular Interventions, 2020, 96, 255-265.	1.7	4
21	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovascular Revascularization Medicine, 2020, 21, 1057-1062.	0.8	23
22	Ventricular arrhythmias in patients with functional mitral regurgitation and implantable cardiac devices: implications of mitral valve repair with MitraclipÂ®. Annals of Translational Medicine, 2020, 8, 956-956.	1.7	2
23	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.6	75
24	Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet, The, 2020, 395, 1487-1495.	13.7	104
25	Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. American Journal of Cardiology, 2020, 129, 122-124.	1.6	5
26	Longâ€term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction. Catheterization and Cardiovascular Interventions, 2020, 96, 831-838.	1.7	2
27	Antithrombotic therapy: less is more or the more the better?. Europace, 2020, 22, 1142-1142.	1.7	1
28	MitraClip Treatment of Secondary Mitral Regurgitation in Heart Failure with Reduced Ejection Fraction: Lessons and Implications from Trials and Registries. Structural Heart, 2020, 4, 247-253.	0.6	5
29	Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2020, 21, 751-758.	1.5	15
30	Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention, 2020, 15, 1548-1554.	3.2	25
31	Left ventricular reverse remodelling predicts longâ€term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. European Journal of Heart Failure, 2019, 21, 196-204.	7.1	47
32	Impact of Diabetes onÂClinical Outcomes After Polymer-Free Amphilimus- and Biolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 1745-1747.	2.9	2
33	Percutaneous Repair for Secondary Mitral Regurgitation. New England Journal of Medicine, 2019, 380, 1975-1978.	27.0	2
34	Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Internal and Emergency Medicine, 2019, 14, 1259-1270.	2.0	24
35	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 972-979.	1.7	5
36	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		5

#	Article	IF	Citations
37	Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion. Heart, 2019, 105, 1096-1102.	2.9	19
38	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	3.9	30
39	Relationship between Syntax Score and prognostic localization of coronary artery lesions with conventional risk factors, plasma profile markers, and carotid atherosclerosis (CAPP Study 2). International Journal of Cardiology, 2018, 257, 306-311.	1.7	11
40	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). International Journal of Cardiology, 2018, 260, 36-41.	1.7	15
41	Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry. International Journal of Cardiology, 2018, 258, 36-41.	1.7	7
42	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 234.	6.1	46
43	Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104, 306-312.	2.9	77
44	Reducer, extracorporeal shockwave therapy or stem cells in refractory angina. Journal of Cardiovascular Medicine, 2018, 19, 42-44.	1.5	4
45	Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment. Journal of Cardiovascular Medicine, 2018, 19, 564-570.	1.5	1
46	Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. Journal of Cardiovascular Medicine, 2018, 19, 351-356.	1.5	4
47	Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation. European Journal of Heart Failure, 2018, 20, 1495-1496.	7.1	6
48	Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 269, 33-39.	1.7	42
49	Effects of drug-eluting stents after rotational atherectomy. Journal of Cardiovascular Medicine, 2017, 18, 354-358.	1.5	2
50	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
51	A Novel Technique for Prosthetic Valve Retrieval After Transcatheter Aortic Valve Embolization. Canadian Journal of Cardiology, 2017, 33, 951.e1-951.e3.	1.7	2
52	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <scp>STATIPLAT</scp> randomized study. Clinical Cardiology, 2017, 40, 605-611.	1.8	9
53	TCT-580 Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Journal of the American College of Cardiology, 2017, 70, B240-B241.	2.8	0
54	Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. International Journal of Cardiology, 2017, 245, 69-76.	1.7	16

#	Article	IF	Citations
55	Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clinical Drug Investigation, 2017, 37, 105-120.	2.2	3
56	Analysis of a Low Dose Protocol to Reduce Patient Radiation Exposure During Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 119, 203-209.	1.6	12
57	Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. American Journal of Cardiovascular Disease, 2017, 7, 9-18.	0.5	6
58	Young Patient with Advanced Heart Failure No Longer a Candidate for Heart Transplantation after MitraClipÃ‚Â® Procedure. Journal of Heart Valve Disease, 2017, 26, 234-236.	0.5	7
59	Drug-eluting stent use after coronary atherectomy. Journal of Cardiovascular Medicine, 2016, 17, 665-672.	1.5	6
60	Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in patients with functional mitral regurgitation. IJC Heart and Vasculature, 2016, 11, 90-98.	1.1	26
61	Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy. American Journal of Cardiology, 2016, 117, 1558-1561.	1.6	2
62	Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. International Journal of Cardiology, 2016, 223, 574-580.	1.7	45
63	Predictors of restenosis following contemporary subintimal tracking and reentry technique: The importance of final <scp>TIMI</scp> flow grade. Catheterization and Cardiovascular Interventions, 2016, 87, 884-892.	1.7	32
64	One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	1.7	25
65	Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 221, 97-106.	1.7	66
66	Radiation Exposure and Contrast Agent Reduction During Transcatheter Aortic Valve Implantation: An Ongoing Experience. Journal of Invasive Cardiology, 2016, 28, 459-465.	0.4	1
67	Clinical outcomes of realâ€world patients treated with an amphilimus polymerâ€free stent versus new generation everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
68	PFO closure with only fluoroscopic guidance: 7 years realâ€world single centre experience. Catheterization and Cardiovascular Interventions, 2015, 86, 105-112.	1.7	10
69	Complications of Percutaneous Coronary Intervention. , 2015, , 2297-2322.		2
70	PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy. Platelets, 2014, 25, 337-342.	2.3	1
71	Differences in the Clinical and Angiographic Characteristics of Chronic Total Occlusion Lesions in the Three Major Coronary Arteries. Journal of Interventional Cardiology, 2014, 27, 44-49.	1.2	14
72	Do Patients Undergoing MitraClip Implantation Require Routine ICU Admission?. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1479-1483.	1.3	18

#	Article	IF	Citations
73	Association of LOXIN, a new functional splicing isoform of the OLR1 gene, with severity and prognostic localization of critical coronary artery stenoses. Journal of Cardiovascular Medicine, 2014, 15, 391-396.	1.5	6
74	First-in-Man MitraClip Implantation to Treat Late Postoperative Systolic Anterior Motion. Circulation: Cardiovascular Interventions, 2014, 7, 860-862.	3.9	13
75	Prognostic role of stress/rest myocardial perfusion scintigraphy in patients with cardiac syndrome x. International Journal of Cardiology, 2014, 173, 467-471.	1.7	10
76	Management of large coronary dissection after STAR. Cardiovascular Revascularization Medicine, 2014, 15, 58-60.	0.8	4
77	The impact of main branch restenosis on long term mortality following drugâ€eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 84, 341-348.	1.7	18
78	Comparison of abluminal biodegradable polymer biolimusâ€eluting stents and durable polymer everolimusâ€eluting stents in the treatment of coronary bifurcations. Catheterization and Cardiovascular Interventions, 2014, 83, 889-895.	1.7	8
79	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. International Journal of Cardiology, 2014, 177, 11-16.	1.7	8
80	Complications of Percutaneous Coronary Intervention. , 2014, , 1-30.		1
81	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
82	Resultados a muy largo plazo tras la implantaciÃ³n de stents liberadores de fÃ¡rmacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. Revista Espanola De Cardiologia, 2013, 66, 24-33.	1.2	10
83	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. International Journal of Cardiology, 2013, 168, 1402-1409.	1.7	73
84	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. Revista Espanola De Cardiologia (English Ed), 2013, 66, 24-33.	0.6	3
85	Heyde's Syndrome Incidence and Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 61, 687-689.	2.8	73
86	Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated. International Journal of Cardiology, 2013, 168, 3791-3796.	1.7	9
87	The Long-Term Clinical Outcome of T-Stenting and Small Protrusion Technique for Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 554-561.	2.9	22
88	Impact of target vessel on longâ€term survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	1.7	46
89	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
90	Estimating incidence of organ cancer related to PCI radiation exposure in patients treated for acute and chronic total occlusions. Journal of Invasive Cardiology, 2013, 25, 441-5.	0.4	18

#	Article	IF	Citations
91	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. Circulation: Cardiovascular Interventions, 2012, 5, 491-498.	3.9	29
92	Aortic Valvuloplasty as Bridging for TAVI in High-Risk Patients with Heydeâ€™s Syndrome: A Case Report. Case Reports in Medicine, 2012, 2012, 1-3.	0.7	9
93	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21
94	An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. PLoS ONE, 2012, 7, e39484.	2.5	52
95	Resolute italian study in all comers. Catheterization and Cardiovascular Interventions, 2012, 79, 567-574.	1.7	9
96	Retrograde popliteal access as bailâ€out strategy for challenging occlusions of the superficial femoral artery: A multicenter registry. Catheterization and Cardiovascular Interventions, 2012, 79, 1188-1193.	1.7	27
97	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
98	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43
99	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	3.2	21
100	Transseptal access for MitraClipÂ® procedures using surgical diathermy under echocardiographic guidance. EuroIntervention, 2012, 8, 579-586.	3.2	19
101	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	2.9	260
102	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 924-931.	1.6	41
103	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. American Journal of Cardiology, 2011, 108, 1055-1060.	1.6	19
104	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. Cardiovascular Revascularization Medicine, 2011, 12, 220-227.	0.8	10
105	Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2011, 4, 387-395.	3.9	41
106	Clinical trial experience with the MitraClip catheter based mitral valve repair system. International Journal of Cardiovascular Imaging, 2011, 27, 1155-1164.	1.5	12
107	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66
108	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62

#	Article	IF	Citations
109	Predictors of moderateâ€toâ€severe paravalvular aortic regurgitation immediately after corevalve implantation and the impact of postdilatation. Catheterization and Cardiovascular Interventions, 2011, 78, 432-443.	1.7	125
110	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
111	Trans-apical and trans-axillary percutaneous aortic valve implantation as alternatives to the femoral route: short- and middle-term results. European Journal of Cardio-thoracic Surgery, 2011, 40, 49-55.	1.4	44
112	How should I treat a long and huge coronary pseudoaneurysm after spontaneous coronary artery dissection?. EuroIntervention, 2011, 6, 1131-1136.	3.2	4
113	Treatment of iatrogenic occlusive coronary dissections: a novel approach. EuroIntervention, 2011, 7, 106-111.	3.2	16
114	The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIENâ„¢ and Medtronic CoreValve ReValving SystemÂ® devices: the Milan registry. EuroIntervention, 2011, 7, 556-563.	3.2	80
115	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136
116	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
117	Prolonged Double Antiplatelet Therapy in a Cohort of â€œDe Novoâ€•Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
118	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. American Journal of Cardiology, 2010, 106, 1721-1727.	1.6	45
119	A new technique for vascular access management in transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 75, 784-793.	1.7	123
120	Coronary Left Main and Nonâ€Left Main Bifurcation Angles: How are the Angles Modified by Different Bifurcation Stenting Techniques?. Journal of Interventional Cardiology, 2010, 23, 382-393.	1.2	17
121	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
122	Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 24-30.	2.0	28
123	Emerging Approaches of Transcatheter Valve Repair/Insertion. Cardiology Research and Practice, 2010, 2010, 1-11.	1.1	8
124	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
125	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14
126	Long-Term Follow-Up on a Large Cohort of â€œFull-Metal Jacketâ€•Percutaneous Coronary Intervention Procedures. Circulation: Cardiovascular Interventions, 2009, 2, 416-422.	3.9	54

#	Article	IF	Citations
127	Crossing CTOsâ€"The tips, tricks, and specialist Kit that can mean the difference between success and failure. Catheterization and Cardiovascular Interventions, 2009, 74, 1019-1046.	1.7	44
128	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. Thrombosis Journal, 2009, 7, 4.	2.1	45
129	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1219-1226.	2.9	28
130	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. EuroIntervention, 2009, 5, 370-374.	3.2	78
131	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation. JACC: Cardiovascular Interventions, 2008, 1, 56-61.	2.9	85
132	CTO recanalization by intraocclusion injection of contrast: The microchannel technique. Catheterization and Cardiovascular Interventions, 2008, 71, 20-26.	1.7	49
133	Subintimal tracking and reâ€entry technique with contrast guidanc: A safer approach. Catheterization and Cardiovascular Interventions, 2008, 72, 790-796.	1.7	105
134	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33
135	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 1477-1481.	1.6	23
136	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. American Heart Journal, 2008, 156, 745-750.	2.7	25
137	Expansion of T-Cell Receptor Î¶^{dim}Effector T Cells in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2305-2311.	2.4	25
138	Multifocal, Persistent Cardiac Uptake of [18-F]-Fluoro-Deoxy-Glucose Detected by Positron Emission Tomography in Patients With Acute Myocardial Infarction. Circulation Journal, 2008, 72, 1821-1828.	1.6	7
139	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation, 2007, 116, 745-754.	1.6	430
140	Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: A multicenter prospective registry of 150 consecutive patients. Catheterization and Cardiovascular Interventions, 2007, 69, 416-424.	1.7	38
141	Percutaneous Coronary Intervention in Patients With a Single Remaining Vessel. American Journal of Cardiology, 2007, 99, 470-471.	1.6	3
142	Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. American Journal of Cardiology, 2007, 99, 916-920.	1.6	26
143	Drug-eluting stent implantation in coronary trifurcation lesions. Journal of Invasive Cardiology, 2007, 19, 157-62.	0.4	9
144	Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. European Heart Journal, 2006, 27, 2330-2337.	2.2	59

#	Article	IF	Citations
145	Patient selection for trans-catheter mitral valve repair versus replacement: ongoing indications and glimpse to the future. Vessel Plus, 0, 2021, .	0.4	1